Synergistic Antitumor Effects of Endostar in Combination with Oxaliplatin via Inhibition of HIF and CXCR4 in the Colorectal Cell Line SW1116

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Jin, Fengyan ^a,b,c   Ji, Huifan ^a   Jia, Chunshu ^a   Brockmeier, Ulf ^d   Hermann, Dirk M ^c   Metzen, Eric ^d   Zhu, Yingqiao ^a   Chi, Baorong ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Jilin Province Tumor Hospital   (China)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; OXALIPLATIN; RECOMBINANT ENDOSTATIN; RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COLONY FORMATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPOXIA; IN VITRO STUDY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL ADHESION; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; COLLAGEN; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOSTATINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LAMININ; NEOPLASM INVASIVENESS; ORGANOPLATINUM COMPOUNDS; PROTEOGLYCANS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 84867375369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047161     Document Type: Article

References (34)

1. Parker SL, Tong T, Bolden S, Wingo PA, (1997) Cancer statistics, 1997. CA Cancer J Clin 47: 5-27.
2. Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, et al. (2000) Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA, eds, Tumours of the digestive system-World Health Organization. Classification of Tumuors. Lyon, France, IARC Press: 105-119.
3. Ingold B, Schulz S, Budczies J, Neumann U, Ebert MP, et al. (2009) The role of vascular CXCR4 expression in colorectal carcinoma. Histopathology 55: 576-86.
4. Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, et al. (2006) Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 12: 2795-803.
5. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, et al. (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23: 2744-53.
6. Dessein AF, Stechly L, Jonckheere N, Dumont P, Monté D, et al. (2010) Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 70: 4644-54.
7. Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, et al. (2010) CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70: 10411-21.
8. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, et al. (2011) Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 71: 603-13.
9. Feng Y, Broder CC, Kennedy PE, Berger EA, (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-7.
10. Egawa T, Kawabata K, Kawamoto H, Amada K, Okamoto R, et al. (2001) The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity 15: 323-34.
11. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201: 1307-18.
12. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, et al. (2002) Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 99: 2703-11.
13. Strasser GA, Kaminker JS, Tessier-Lavigne M, (2010) Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 115: 5102-10.
14. Müller A, Homey B, Soto H, Ge N, Catron D, et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-6.
15. Teicher BA, Fricker SP, (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-31.
16. Hao J, Song X, Song B, Liu Y, Wei L, et al. (2008) Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 15: 449-55.
17. Liu F, Wang P, Jiang X, Tan G, Qiao H, et al. (2008) Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99: 2055-61.
18. Nardinocchi L, Puca R, Sacchi A, D'Orazi G, (2009) Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer (8) (): 1.
19. Rapisarda A, Melillo G, (2009) Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12: 74-80.
20. Folkman J, (2006) Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 312: 594-607.
21. Abdollahi A, Hlatky L, Huber PE, (2005) Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74.
22. Perletti G, Concari P, Giardini R, Marras E, Piccinini F, et al. (2000) Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60: 1793-6.
23. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, et al. (2004) Endostatin's antiangiogenic signaling network. Mol Cell 13: 649-63.
24. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, et al. (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-3.
25. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, et al. (2006) Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 24: 3555-61.
26. Han B, Xiu Q, Wang H, Shen J, Gu A, et al. (2011) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 6: 1104-9.
27. Zhou JF, Bai CM, Wang YZ, Li XY, Cheng YJ, et al. (2011) Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J (Engl) 124: 4299-303.
28. Jia Y, Liu M, Cao L, Zhao X, Wu J, et al. (2011) Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol 32: 316-24.
29. Wylie PG, Bowen WP, (2007) Determination of cell colony formation in a high-content screening assay. Clin Lab Med 27: 193-9.
30. Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, et al. (2003) Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther 2: 845-54.
31. Faye C, Moreau C, Chautard E, Jetne R, Fukai N, et al. (2009) Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem 284: 22029-40.
32. Yu Y, Moulton KS, Khan MK, Vineberg S, Boye E, et al. (2004) E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci U S A 101: 8005-10.
33. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, et al. (2010) HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176: 2292-301.
34. Dewhirst MW, Cao Y, Li CY, Moeller B, (2007) Exploring the role of HIF-1 in early angiogenesis and response to radiotherapy. Radiother Oncol 83: 249-55.